Skip to content
Buy This GLP
← Research
Evidence

Semaglutide With Automated Insulin Delivery in Type 1 Diabetes

In a 26-week trial, 36% of adults on semaglutide met a combined glucose and weight target. Every participant already used automated insulin delivery.

Editorial profile: Neil SandersBuy This GLP Editorial Team4 min read
Met all three targets at 26 weekssemaglutide36%placebo0%72 adults, all using an automated insulin delivery system

Seventy-two adults already using automated insulin delivery joined the trial [1]. The question of whether a GLP-1 can replace insulin is distinct from adding one. Both trial groups continued insulin.

What the trial measured

Adults with type 1 diabetes and obesity received weekly semaglutide up to 1 mg or placebo for 26 weeks [1]. The main outcome required meeting three targets. Glucose had to stay between 70 and 180 mg/dL more than 70% of the time. Time below 70 mg/dL had to be under 4%. Participants also had to lose at least 5% of their weight.

Thirty-six percent of the semaglutide group met all three targets. None in the placebo group did. The difference was 36 percentage points, with a 95% confidence interval of 20.6 to 52.2. Time in range improved by 8.8 percentage points more with semaglutide. The difference in average weight change was 8.8 kg in favor of semaglutide.

What the safety results can tell us

Each group had two severe low blood sugar events. The researchers reported no diabetic ketoacidosis in either group. An earlier crossover trial reported two episodes of ketosis with normal glucose during semaglutide use [2]. Neither episode progressed to ketoacidosis.

Ozempic’s FDA label does not include treatment of type 1 diabetes [3]. The differences between semaglutide brands matter when checking a product’s approved uses. This trial cannot establish safety over longer periods or in people using insulin injections alone.

Frequently asked

Can semaglutide replace insulin in type 1 diabetes?
No. All participants continued automated insulin delivery. The trial tested adding semaglutide to insulin.
What was the main outcome?
Thirty-six percent on semaglutide and none on placebo met all three glucose and weight targets by week 26.
Did the trial report ketoacidosis?
It reported no diabetic ketoacidosis. Each group had two severe low blood sugar events.

Sources

  1. [1] Shah VN, et al. (2025). Semaglutide in Adults with Type 1 Diabetes and Obesity NEJM Evidence. PMID 40550013
  2. [2] Pasqua MR, et al. (2025). Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes Nature Medicine. Source
  3. [3] Novo Nordisk Inc. (2026). Ozempic injection prescribing information, section 1 DailyMed, U.S. National Library of Medicine. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence